Delphi Management Partners VIII’s Karyopharm Therapeutics KPTI Stock Holding History

Delphi Management Partners VIII’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$13.2M	Hold	150,867	–	–	9.51%	2
2021 Q2	$23.4M	Hold	150,867	–	–	18.44%	2
2021 Q1	$23.8M	Hold	150,867	–	–	16.44%	3
2020 Q4	$35M	Buy	+150,867	New	+$35M	23.03%	2
2019 Q4	$43.4M	Buy	+150,867	New	+$32.7M	34.24%	2

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Delphi Management Partners VIII's KPTI Position: Q3 2021 in Review

Delphi Management Partners VIII held its Karyopharm Therapeutics (KPTI) position steady in Q3 2021 at 150,867 shares worth $13.2M. The position accounts for 9.51% of the portfolio, ranked #2.

Delphi Management Partners VIII first reported a position in KPTI in Q4 2019 and has held it in 5 quarters since. The position peaked at $43.4M in Q4 2019. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

Delphi Management Partners VIII held 150,867 shares of Karyopharm Therapeutics worth $13.2M as of Q3 2021.
Delphi Management Partners VIII left its Karyopharm Therapeutics share count unchanged in Q3 2021.
Karyopharm Therapeutics made up 9.51% of Delphi Management Partners VIII's portfolio in Q3 2021, its #2 holding.
Delphi Management Partners VIII first reported a position in Karyopharm Therapeutics in Q4 2019 and has held it in 5 quarters since.
Delphi Management Partners VIII's Karyopharm Therapeutics position peaked at $43.4M in Q4 2019.
134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Delphi Management Partners VIII's 13F filing for Q3 2021, filed 15 Nov 2021.